Anticancer research
-
Anticancer research · Sep 2008
Clinical TrialBladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer.
Patient-reported toxicity in two radiotherapy regimens for early stage prostate cancer was investigated. In 2003, the Swedish BeamCath technique was adapted for Northern Norway. ⋯ Eighty patients responded, which represents 89% of all patients. The treatment group (23 patients) had received 76 Gy with the BeamCath technique and the control group (57 patients) received 70 Gy employing a conformal technique. The BeamCath technique was associated with a lower median rectal (p=0.004; 50.6 Gy versus 56.2 Gy) and bladder dose (p=0.017; 48.5 Gy versus 61.5 Gy). There were no differences in scores on masculinity and sexual function. In conclusion, the BeamCath technique did not increase rectal or bladder toxicity.
-
Anticancer research · Sep 2008
ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
The usefulness of serum pro-gastrin-releasing peptide (ProGRP) as a tumor marker in patients with small cell lung cancer has recently drawn the attention of many research centers. The aim of the study was the evaluation of ProGRP, neuron-specific enolase (NSE), soluble fragment of cytokeratin 19 (CYFRA 21-1) and lactate dehydrogenase (LDH) levels at the time of diagnosis and during chemo- and radiotherapy of small cell lung cancer patients with limited disease (SCLC-LD). The studies were performed on a group of 64 patients with SCLC-LD who had received no prior therapy. ⋯ Differences in NSE levels were only significant for the first two courses and follow-up. Univariate analysis showed significant relationships between disease-free survival and the initial levels of NSE and CYFRA 21-1 as well as between overall survival and prophylactic cranial irradiation (PCI) and the initial ProGRP, NSE and CYFRA 21-1 levels. Changes of ProGRP level seem to be more precise than NSE as a tool for monitoring therapy in SCLC patients with limited disease, but for prediction of relapse, in addition to NSE determinations of ProGRP seem to be optimal.
-
Anticancer research · Jul 2008
CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas.
Genetic polymorphisms in metabolizing enzymes may modify the association of environmental exposure on colorectal cancer (CRC) and adenoma risk. ⋯ These findings may indicate that the association between cigarette smoking and colorectal carcinogenesis can be modified by the CYP1A2 genotype.
-
Anticancer research · Jul 2008
Phase I study of biweekly docetaxel and S-1 combination chemotherapy for advanced gastric cancer.
Docetaxel and S-1 are novel antitumour chemotherapeutic agents with distinct toxicities. Here a phase I study of combined docetaxel and S-1 therapy for advanced gastric cancer is reported. ⋯ A phase II clinical trial is required to confirm these results.
-
It is unclear whether there is a relationship between type two diabetes and cancer mortality. It also is unclear whether obesity and body mass index (BMI) are associated with cancer in type 2 diabetes patients. ⋯ An increased cancer mortality rate was found in type two diabetes mellitus patients but there was no significant association between BMI or obesity and cancer mortality.